Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meredith M Regan

Showing results (71-80 of 259) with videos related to

Pageof 26
Sort By:
Immunotherapy|January 30, 2020
Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinomaApoorva Ambavane, Shuo Yang, Michael B Atkins, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 8, 2018
Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysisDavid F McDermott, Ruchit Shah, Komal Gupte-Singh, et al.
The Journal of Urology|October 24, 2002
Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomyGlenn J Bubley, Steve P Balk, Meredith M Regan, et al.
Melanoma Research|December 2, 2021
Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitorsCharlene M Mantia, Lillian Werner, Brian Stwalley, et al.
BJU International|March 18, 2011
Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapyDipika Misra, Wanling Xie, Meredith M Regan, et al.
Fertility and Sterility|June 18, 2009
A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trialRichard H Reindollar, Meredith M Regan, Peter J Neumann, et al.
Journal of the American College of Cardiology|February 21, 2004
Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular riskHans K Meier-Ewert, Paul M Ridker, Nader Rifai, et al.
Future Oncology (London, England)|April 25, 2022
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ <i>PIK3CA</i>-mutated breast cancerJose Alejandro Pérez-Fidalgo, Carmen Criscitiello, Eva Carrasco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2009
Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancerJune M Chan, William K Oh, Wanling Xie, et al.
Journal for Immunotherapy of Cancer|January 30, 2026
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinomaHollis Viray, Charlene M Mantia, Opeyemi A Jegede, et al.
Pageof 26

Showing results (71-80 of 259) with videos related to

Sort By:
Pageof 26
Immunotherapy|January 30, 2020
Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinomaApoorva Ambavane, Shuo Yang, Michael B Atkins, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 8, 2018
Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysisDavid F McDermott, Ruchit Shah, Komal Gupte-Singh, et al.
The Journal of Urology|October 24, 2002
Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomyGlenn J Bubley, Steve P Balk, Meredith M Regan, et al.
Melanoma Research|December 2, 2021
Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitorsCharlene M Mantia, Lillian Werner, Brian Stwalley, et al.
BJU International|March 18, 2011
Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapyDipika Misra, Wanling Xie, Meredith M Regan, et al.
Fertility and Sterility|June 18, 2009
A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trialRichard H Reindollar, Meredith M Regan, Peter J Neumann, et al.
Journal of the American College of Cardiology|February 21, 2004
Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular riskHans K Meier-Ewert, Paul M Ridker, Nader Rifai, et al.
Future Oncology (London, England)|April 25, 2022
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ <i>PIK3CA</i>-mutated breast cancerJose Alejandro Pérez-Fidalgo, Carmen Criscitiello, Eva Carrasco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2009
Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancerJune M Chan, William K Oh, Wanling Xie, et al.
Journal for Immunotherapy of Cancer|January 30, 2026
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinomaHollis Viray, Charlene M Mantia, Opeyemi A Jegede, et al.
Pageof 26